Back to rankings

Waters Corp (WAT)

Overvalued
HealthcareDiagnostics & ResearchUnited States

Fundamental

50

Price

$439.39

Market Cap

$43.49B

Part 1 · What the company is worth

Overview

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products, as well as for life science research; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology, which is used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balance Sheet & Liquidity

Revenue

$4.64B

Trailing 12 months (through 7/4/2026)

Net Income

$166M

Trailing 12 months (through 7/4/2026)

Free Cash Flow

$540M

Total Equity

$2.56B

Total Liabilities

$2.52B

Current Ratio

1.86

Interest Coverage

2.21

Debt/EBITDA

3.62

Earnings Per Share

Revenue & Net Income

Free Cash Flow

Income Breakdown

Historical statement

Margins over time

Debt over time

How heavy the debt is

Growth grid

Growth — Revenue

Fair Value Estimation

General caseOvervalued

Fair Value

$312.84

Current Price

$439.39

Margin of Safety

-40.5%

Fair Value Range

$203.35 - $422.33

Spread across the valuation methods used, not a statistically calibrated confidence interval.

Estimation Methods

Analyst price target:$444.79
Discounted cash flow (DCF):$87.65
Earnings multiple (P/E):$103.45
Graham growth formula:$65.63
Earnings power value (EPV):$24.06
Justified P/B:Not enough data to compute it
Dividend discount (Gordon):Not enough data to compute it
P/FFO, funds from operations:Not enough data to compute it
Mid-cycle earnings:$258.21
Revenue multiple:$186.33
Analyst Consensus:Buy (20B / 11H / 0S)
Last Earnings Surprise:+0.44%

Valuation Metrics

P/E Ratio

109.57

ROE

25.1%

P/B Ratio

2.84

P/FCF

80.62

Gross Margin

59.3%

ROIC

1.2%

Profitability Radar

Value Creation (Economic Moat)

ROIC

1.2%

WACC

10.0%

ROIC − WACC

-8.8 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Fundamental Analysis Criteria

Passed (18)

  • EPS shows upward trend
  • EPS CAGR 8.16%
  • Price CAGR 11.76%
  • Gross Margin 59.3%
  • P/B Ratio 2.84
  • Debt/Equity ratio
  • Operating Margin 7.1%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Revenue Growth 5Y 6.0%
  • Analyst Consensus 65% Buy
  • Earnings Surprise avg 4.9%
  • Earnings Quality (OCF/NI) 1.02
  • Share Dilution 0.3%
  • Piotroski F-Score 5/9

Failed (9)

  • ROIC 1.2%
  • P/FCF 80.62
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • ROE 1.9%
  • PEG Ratio 50.28
  • Net Margin Trend 20.3% vs 21.6%

Unavailable (1)

  • Dividend Payout NaN%

Piotroski F-Score

5/9

Mixed signals: some areas need attention

score
criteria

Earnings Quality

1.02

High quality: earnings backed by cash

Share Dilution

0.3%

Share count is stable

Institutional Holdings

Governance

Executive Team

NameTitleAge
Dr. Udit Batra Ph.D.President, CEO & Director54
Mr. Amol ChaubalSenior VP & CFO48
Ms. Jianqing Y. BennettSenior Vice President of Waters Advanced Diagnostics Division55
Mr. Christos RossSenior Vice President of Global Operations-
Mr. Brook M. ColangeloSenior VP & Chief Information Officer47
Mr. Caspar TudorHead of Investor Relations-
Ms. Keeley A. Aleman J.D.Senior VP, General Counsel, Head of Global Human Resources & Corporate Secretary48
Ms. Kristen GarveySenior Vice President of Global Communications-
Dr. Daniel Rush Ph.D.Senior Vice President of Global Research & Strategy-
Mr. Allan JaenickeSenior Vice President of Transformation-

Audit Risk

8

Board Risk

5

Compensation Risk

7

Shareholder Rights Risk

4

Part 2 · The price and when to enter

This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.

Documents

  • Annual Report (10-K)

    A yearly overview of the business, its financial results, and the risks it faces.

    Filed on 2026-02-23

    View document
  • Quarterly Report (10-Q)

    A snapshot of financial performance for the most recent three-month period.

    Filed on 2026-08-11

    View document
  • Current Report (8-K)

    An announcement of a major event, such as a leadership change or big news.

    Filed on 2026-08-21

    View document

via SEC EDGAR

Income History

via SEC EDGAR

Latest News

Recent headlines for WAT, sourced from Markets Gazette.

No recent news for WAT.